by Mat Dirjish
Heralded as the most medically advance hybrid smartwatch, Withings’ ScanWatch holds title as the first wearable device to receive FDA clearance for both atrial fibrillation detection through medical grade ECGs and measuring SpO2 levels from the wrist. First announced in 2020, the smartwatch also snagged three CES Innovation Awards.
ScanWatch features a stainless-steel case, durable sapphire glass watch face, and a large digital display. User navigation is via a unique crown dial. Additionally, ScanWatch is water-resistant up to 5 ATM and specifies a battery life up to 30 days.
According to the company, atrial fibrillation (AFib) is often underdiagnosed as it can be intermittent and missed if symptoms do not occur during doctor visits. Via the ability to take a medical-grade ECG on-demand, ScanWatch can detect if a user has AFib. It can monitor heart rate through its PPG sensor and, when ScanWatch detects an irregular heartbeat, it will prompt the user to record an ECG in just 30 seconds via the watch display.
With FDA Clearance of its SpO2 functionality, ScanWatch can monitor blood oxygen levels and detect if the wearer is experiencing issues from respiratory disorders such as COPD or COVID. Using an algorithm that analyzes blood oxygen levels, heart rate, movement, and respiratory rate, it can also detect the presence of nighttime breathing disturbances, a sign of sleep apnea.
Finally, ScanWatch connects with the company’s free Health Mate app, which provides data and insights and can schedule activity reminders, set goals, and manage achievements. ScanWatch will be available early November, 2021. Prices are $279 for the 38-mm model and $299 for the 42-mm version. Either comes in a choice of black or white faces.
Ready to start clocking your vital signs but desire further illumination? If so, peruse the ScanWatch overview.
| email@example.com | 1-516-422-1431 |